- Home
- FBRX vs INMD Comparison
FBRX vs INMD Comparison
Compare FBRX & INMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FBRX | INMD |
|---|---|---|
| Founded | N/A | 2008 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 899.4M | 842.0M |
| IPO Year | 2017 | 2018 |
Fundamental Metrics
Financial Performance| Metric | FBRX | INMD |
|---|---|---|
| Price | $77.00 | $14.89 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 5 |
| Target Price | ★ $67.00 | $17.33 |
| AVG Volume (30 Days) | ★ 1.4M | 390.7K |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.30 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $36,000.00 | N/A |
| Revenue This Year | N/A | $1.74 |
| Revenue Next Year | N/A | $3.26 |
| P/E Ratio | ★ N/A | $10.11 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.18 | $12.72 |
| 52 Week High | $77.20 | $16.74 |
Technical Indicators
Market Signals| Indicator | FBRX | INMD |
|---|---|---|
| Relative Strength Index (RSI) | 84.34 | 44.86 |
| Support Level | $26.85 | $13.27 |
| Resistance Level | $77.20 | $15.28 |
| Average True Range (ATR) | 0.07 | 0.18 |
| MACD | -1.75 | -0.05 |
| Stochastic Oscillator | 83.33 | 18.00 |
Price Performance
Historical ComparisonAbout FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.
About INMD InMode Ltd.
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF, and Morpheus8, among others. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia, Israel, and other regions.